Characterizing the exposure–response relationship of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma by Jamie N. Connarn, Han Witjes, Marielle van Zutphen‐van Geffen, Rik deGreef, Timothy B. Campbell, Kristen Hege, Simon Zhou, Manisha Lamba

Get full text

Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies by Amy Easton, Marianne L. Jensen, Congwei Wang, Peter H. Hagedorn, Yuwen Li, Michael Weed, Jere E. Meredith, Valerie Guss, Kelli Jones, Martin Gill, Carol Krause, Jeffrey M. Brown, Lisa Hunihan, Joanne Natale, Alda Fernandes, Yifeng Lu, Joe Polino, Mark Bookbinder, Greg Cadelina, Yulia Benitex, Ramola Sane, John Morrison, Dieter Drexler, Stephen E. Mercer, Charlotte Bon, Nikhil J. Pandya, Ravi Jagasia, Tai-Hsien Ou Yang, Tania Distler, Fiona Grüninger, Michael Meldgaard, Marco Terrigno, John E. Macor, Charles F. Albright, James Loy, Anja M. Hoeg, Richard E. Olson, Angela M. Cacace

Get full text

Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its associatio... by Rao Prabhala, Rao Prabhala, Rao Prabhala, William E. Pierceall, Mehmet Samur, Mehmet Samur, Lakshmi B. Potluri, Kevin Hong, Teresa Peluso, Srikanth Talluri, Angela Wang, Aishwarya Katiki, Sahan D. Vangala, Michael Buonopane, Vaishnavi Bade, Hannah Seah, Arthur Krogman, Sanika Derebail, Mariateresa Fulciniti, Suzan B. Lazo, Paul Richardson, Paul Richardson, Kenneth Anderson, Kenneth Anderson, Jill Corre, Herve Avet-Loiseau, Anjan Thakurta, Anjan Thakurta, Nikhil Munshi, Nikhil Munshi, Nikhil Munshi

Get full text

329 Prolonged overall survival (OS) in patients with metastatic colorectal cancer (mCRC) in SPICE, a phase I study of enadenotucirev in combination with nivolumab by Richard Brown, John Beadle, Tom Lillie, Andrew Stone, Sarah Lockwood, Andrew Fox, Eirini Bournazou

238 Molecular dissection of tumor-immune microenvironment factors associated with response to checkpoint inhibitor therapy in non-small cell lung cancer patients using nanostring d... by Brandon Higgs, Jordan Blum, Omar Jabado, Suzana Couto, Patrick Franken, Patricia Coutinho de Souza, Nora Pencheva, Kate Sasser

449 Concurrent ibrutinib enhances T cell function in patients with chronic lymphocytic leukemia (CLL) treated with lisocabtagene maraleucel (liso-cel), a chimeric antigen receptor... by Julie Rytlewski, Leanne Peiser, Jerill Thorpe, Heidi Gillenwater, Ken Ogasawara, Yeonhee Kim, Diana Shpektor, Eniko Papp

Biocatalytic Synthesis of Chiral Pharmaceutical Intermediates by Ramesh N. Patel

Get full text

292 Ex vivo profiling of PD-1 blockade using an organotypic tissue slice model in solid tumors by David Nelson, Jimena Trillo-Tinoco, Michaela Bowden, Chensheng Zhou, Anne Lewin, Benjamin Chen, Lina Ding, Kristin Sullivan

FINDINGS RELEASED FROM NAXOS, A FRENCH REAL-WORLD DATA ANALYSIS AND THE LARGEST REAL-WORLD DATA ANALYSIS ON ORAL ANTICOAGULANT EFFECTIVENESS AND SAFETY IN EUROPE AMONG PATIENTS WIT... by article Editorial

“…This late-breaking presentation is one of 11 Bristol-Myers Squibb-Pfizer Alliance abstracts being presented at the European Society of Cardiology Congress 2019.…”
Get full text

INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY by JP Sharman, JM Melear, A Yacoub, SR Fanning, DJ Andorsky, GS Nowakowski, MJ Rummel, F Lansigan, J Li, JR Ahn, M Gharibo, M Coleman

Get full text

Preclinical Characterization of the Anti-Leukemia Activity of the CD33/CD16a/NKG2D Immune-Modulating TriNKET^® CC-96191 by Margaret C. Lunn-Halbert, George S. Laszlo, Sarah Erraiss, Mark T. Orr, Heidi K. Jessup, Heather J. Thomas, Henry Chan, Mahan A. Jahromi, Jonathan Lloyd, Ann F. Cheung, Gregory P. Chang, Tanmay Dichwalkar, Daniel Fallon, Asya Grinberg, Eduardo Rodríguez-Arbolí, Sheryl Y. T. Lim, Allie R. Kehret, Jenny Huo, Frances M. Cole, Samuel C. Scharffenberger, Roland B. Walter

Get full text

nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis by Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski

Get full text

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, p... by Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson

Get full text

CTLA4-Ig Prolongs Survival of Microencapsulated Neonatal Porcine Islet Xenografts in Diabetic Nod Mice by Collin J. Weber M.D., D.M.Sci, Mary K. Hagler, John T. Chryssochoos, Judith A. Kapp, Gregory S. Korbutt, Ray V. Rajotte, Peter S. Linsley

Get full text

106 Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel) by Susan Kim, Yue Jiang, Archana Brahmandam, Jim Qin, Brook Barajas, Soraya Carrancio, Leanne Peiser

Extended Treatment with Apixaban for Venous Thromboembolism Prevention in the Netherlands: Clinical and Economic Effects by Lisa A. de Jong, Judith J. Gout-Zwart, Jelena Stevanovic, Harrie Rila, Mike Koops, Menno V. Huisman, Maarten J. Postma

Get full text

Comparative Effectiveness of Abatacept vs. Tofacitinib in Rheumatoid Arthritis Patients who are CCP+ by Leslie R. Harrold, Keith Wittstock, Sheila Kelly, Xue Han, Ying Shan, Lin Guo, Page C. Moore, Vadim Khaychuk

Get full text

New drugs in the treatment of chronic myeloid leukaemia Novas drogas no tratamento da leucemia mielóide crônica by Daniela Cilloni, Antonia Rotolo, Paolo Nicoli, Marco Bosa, Giuseppe Saglio

“…Inibidores de tirosino quinases de segunda geração como o nilotinibe (Tasigna®, Novartis) e o dasatinibe (Sprycel®, Bristol Myers Squibb) têm mostrado significante atividade nos estudos clínicos em paciente onde o imatinibe falhou. …”
Get full text

Correlation between pathologic complete response, event-free survival/disease-free survival and overall survival in neoadjuvant and/or adjuvant HR+/HER2-breast cancer by Anagha Gogate, Sandip Ranjan, Amit Kumar, Hitesh Bhandari, Eros Papademetriou, Inkyu Kim, Ravi Potluri

Get full text

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor by Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, LaCreta F, Frost CE

“…Vijay V Upreti,1 Yan Song,1 Jessie Wang,2 Wonkyung Byon,3 Rebecca A Boyd,3 Janice M Pursley,4 Frank LaCreta,1 Charles E Frost1 1Clinical Pharmacology and Pharmacometrics, Discovery Medicine and Clinical Pharmacology, 2Exploratory Development Global Biometric Sciences, Bristol-Myers Squibb, Princeton, NJ, 3Primary Care Clinical Pharmacology, Pfizer, Groton, CT, 4Analytical and Bioanalytical Department, Bristol-Myers Squibb, Princeton, NJ, USA Background: Apixaban is an oral, selective, direct factor Xa inhibitor approved for thromboprophylaxis after orthopedic surgery and stroke prevention in patients with atrial fibrillation, and under development for treatment of venous thromboembolism. …”
Get full text